Life Tech pairs with Novartis on cancer; Allergan rides device growth to strong Q2;

@FierceMedDev: Alere's losses triple as investor fight awaits. Story | Results | Follow @FierceMedDev

@MarkHFierce: Italy's Sorin has finally recovered from earthquake-related earnings challenges. Story | Follow @MarkHFierce

@DamianFierce: Siemens: Löscher's out; Kaeser's in; revenue's still sagging. Much more here: Report | Follow @DamianFierce

> Life Technologies ($LIFE) has signed a deal with Novartis ($NVS), allowing the drugmaker to use its modified T cell technology for cancer treatments. News

> GE Healthcare ($GE) submitted the final portion of its FDA application for a new breast imaging technology that uses tomosynthesis to provide 3-D images. More

> Allergan ($AGN) reported $1.6 billion in sales last quarter, a 10.6% increase sped along by a strong performance from its medical device business, which grew 7.4% to $229.3 million. Results

> Roche Diagnostics ($RHHBY) has launched a new automation system for its Cobas 8100 analyzers. Release

> Teleflex ($TFX) posted $420.1 million in revenue last quarter, a 9.6% jump, while net income stayed about flat at $42.4 million. Financials

> Episurf Medical won a CE mark for a new implant designed to treat cartilage damage in the knee. Item

Biotech News

@FierceBiotech: From Ex-Yahoo CEO backs genomics big data startup Bina. Article | Follow @FierceBiotech

@JohnCFierce: AstraZeneca commits $815M to partner with FibroGen on anemia drug. News | Follow @JohnCFierce

@RyanMFierce: There are no drugs approved specifically for Fragile X, a top genetic cause of autism and intellectual disability. More | Follow @RyanMFierce

@EmilyMFierce: New compound could combat castration-resistant prostate cancer. Story | Follow @EmilyMFierce

> NIH awards Third Rock startup up to $10M for Fragile X work. Item

> Buzz: Hungry AstraZeneca circles a blockbuster biosimilars buyout. Report

> Cubist splurges on Trius and Optimer buyouts to spur antibiotics growth. Article

> Report: Alexion allies with Goldman as Roche buyout rumor blazes. More

Pharma News

@FiercePharma: ICYMI yesterday: Pfizer unit pleads guilty, agrees to pay $491M in off-label marketing case. Report | Follow @FiercePharma

@CarlyHFierce: Rumors swirling about an AstraZeneca Celltrion buyout, but the Korean co. says nothing is definite. Celltrion's statement | Follow @CarlyHFierce

> FDA clears Merck's Januvia, sister meds of new pancreatitis worries. Story

> Sanofi swaps leaders at animal health unit Merial. Item

> Bayer's new drugs shine, fueling 5.5% pharma growth. Article

Drug Delivery News

@MichaelGFierce: Swedish team creates 'impossible' record-breaking drug delivery material. More | Follow @MichaelGFierce

> Mallinckrodt, Depomed win priority review for oral pain med. Report

> Aussie method makes for smaller, more efficient inhaled drugs. More

> DNA-based molecular robots zero in on cancer, autoimmune diseases. Article

> Mercator snags FDA patent for blood-pressure drug delivery catheters. Item

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.